MINNEAPOLIS–(BUSINESS WIRE)–Be The Match Biotherapies® today announced expanded support for customers in the Northern California region. Chris McClain, Senior Vice President, will work from the San Francisco area to support a growing customer base seeking high-quality cellular source material for allogeneic therapy development and commercialization to deliver urgently needed cellular therapies to patients.
“Be The Match has been a leader in providing clinical grade allogeneic donor cells for over 30 years and has been providing GMP compliant cell starting material to allogeneic cell therapy platform developers since 2016. We couldn’t be more excited to deepen our strategy to focus on these emerging therapies and work more closely with the developers of these therapies located in the San Francisco area and more broadly on the West Coast,” said Chris McClain, Vice President principal of Be The Match BioTherapies.
Since 2016, Be The Match BioTherapies has been providing cell sourcing and supply chain management services for the development of allogeneic cell therapies. He successfully delivered his first cellular starting material for manufacturing only two months after engaging with his first customer. The organization is a trusted partner for more than 50 cell and gene therapy developers ranging from small start-ups to large international companies.
Chris McClain leads the sales and business development team for Be The Match BioTherapies. In this role, he partners with companies developing innovative and life-saving therapies that can leverage the National Marrow Donor Program (NMDP) / Be The Match cell supply, clinical research services and outcome tracking capabilities. .
Prior to joining Be the Match BioTherapies, Chris was co-founder of Nora Therapeutics, Inc., a venture capital-backed biopharmaceutical company developing novel therapies in areas of high unmet reproductive health medical need. He was an advisory member of the Office for Technology Commercialization Venture Center at the University of Minnesota, a guest lecturer in the life sciences program at the Carlson Graduate School of Management at the University of Minnesota, a mentor for the annual MNCup startup and co-chair of Medical Alley’s Biotech Common Interest Group. He earned his Masters in Business Administration and Bachelors in Economics from the University of California, Berkeley.
Be The Match Biotherapies
Be The Match BioTherapies is the only cell and gene therapy solutions provider with customizable services to support the end-to-end cell therapy supply chain. Backed by the cutting-edge experience of the National Bone Marrow Donor Program®/Be the match® and a research partnership with the CIBMTR® (International Blood and Marrow Transplant Research Center®), the organization designs solutions that advance the development of cell and gene therapies around the world.
Be The Match BioTherapies is dedicated to accelerating patient access to life-saving cell and gene therapies by providing high-quality cell source material from the Be The Match registry.®, the world’s most diverse registry of over 7 million potential blood stem cell donors. Through established relationships with apheresis, marrow collection and transplantation centers worldwide, the organization develops, integrates, trains and manages extensive collection networks to advance cell therapies. Be The Match BioTherapies utilizes a proven infrastructure of regulatory compliance and managed logistics experts and cell therapy supply chain case managers to successfully transport and deliver lifesaving, regulatory-compliant therapies around the world . Through CIBMTR, Be The Match BioTherapies is expanding its services beyond the cell therapy supply chain to include long-term monitoring of the first two FDA-approved CAR-T therapies.
For more information, visit www.BeTheMatchBioTherapies.com or follow Be The Match BioTherapies on LinkedIn or Twitter.